Citius Oncology (CTOR) Other Accumulated Expenses (2023 - 2026)

Citius Oncology (CTOR) has 4 years of Other Accumulated Expenses data on file, last reported at $8.2 million in Q1 2026.

• On a quarterly basis, Other Accumulated Expenses rose 66.37% year-over-year to $8.2 million in Q1 2026; TTM through Mar 2026 was $8.2 million, a 66.37% increase from a year earlier, with the FY2025 full-year figure at $9.5 million, up 1515.77% from the prior year.
• Other Accumulated Expenses for Q1 2026 stood at $8.2 million, down from $11.5 million in the prior quarter.
• Over the last five years, Other Accumulated Expenses for CTOR reached as high as $19.5 million in Q3 2023 and fell as low as $344875.0 in Q4 2023.
• Historically, Other Accumulated Expenses has averaged $5.6 million across 4 years, with a median of $3.9 million in 2024.
• Across the five-year window, Other Accumulated Expenses sank 96.98% in 2024 and surged 1515.77% in 2025, its largest moves.
• Year by year, Other Accumulated Expenses stood at $344875.0 in 2023, then surged by 739.82% to $2.9 million in 2024, then jumped by 296.87% to $11.5 million in 2025, then fell by 28.48% to $8.2 million in 2026.
• Per Business Quant data, the three most recent Other Accumulated Expenses figures were $8.2 million in Q1 2026, $11.5 million in Q4 2025, and $9.5 million in Q3 2025.